Upstream Bio News

News

Ticker

UPB

ISIN

US91678A1079

Chiffre d'affaires Résultat net P/E P/S EBIT Dividende Achats de membres du conseil Actions Capitalisation boursière Endettement Passifs Capitaux propres AAQS Effectifs ROE ROA ROCE News Documents

Actualités Eulerpool Upstream Bio

Actualités de l'action Upstream Bio

Upstream Bio est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Upstream Bio.

1 mars·
Benzinga
Upstream Bio Phase 2 VIBRANT Data Showed Primary Endpoint Of Endoscopic Nasal Polyp Score Showed Reduction Of -1.95 (p < 0.0001); Secondary Endpoints Also Provided Strong Efficacy Data In New Analyses
25 février·
Benzinga
Peering Into Upstream Bio Inc's Recent Short Interest
13 février·
ChartMill
Let's take a look at the stocks that are in motion in today's session.
13 février·
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
12 février·
SeekingAlpha
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data
11 février·
ChartMill
Which stocks are experiencing notable movement on Wednesday?
11 février·
ChartMill
Top stock movements in today's session.
11 février·
ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session.
11 février·
ChartMill
Get insights into the top gainers and losers of Wednesday's pre-market session.
11 février·
Benzinga
Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
11 février·
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
11 février·
Benzinga
Upstream Bio Releases Topline Data From Phase 2 VALIANT Trial Of Verekitug For Severe Asthma, Meeting The Primary Endpoint Of Annualized Asthma Exacerbation Rate
8 janvier·
SeekingAlpha
Upstream Bio: Fully Priced After Recent Rally
5 décembre·
SeekingAlpha
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study
26 novembre·
Yahoo
Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge
18 novembre·
Benzinga
Evercore ISI Group Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $40
5 novembre·
Benzinga
Upstream Bio Q3 EPS $(0.63) Beats $(0.76) Estimate, Sales $683.000K Beat $645.000K Estimate
31 octobre·
Yahoo
Upstream Bio to Participate in Upcoming November Investor Conferences
30 septembre·
Yahoo
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
30 septembre·
Benzinga
Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data

Communiqués de presse relatifs à l'action Upstream Bio

Upstream Bio publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

Upstream Bio News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Upstream Bio (UPB, ISIN : US91678A1079). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Upstream Bio.

Upstream Bio Action

Upstream Bio Upstream Bio Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company, which went public on October 11, 2024, is advancing verekitug, a monoclonal antibody targeting TSLP, a key cytokine involved in immune-mediated conditions. It is conducting Phase II trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to expand into COPD treatment.